Shattuck Labs to Present Virtually at Evercore ISI 3rd Annual HealthCONx Conference
Shattuck Labs, a clinical-stage biotechnology company focused on developing bi-functional fusion proteins, announced participation in the Evercore ISI 3rd Annual HealthCONx conference taking place December 1-3, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Shattuck Labs, a clinical-stage biotechnology company focused on developing bi-functional fusion proteins, announced participation in the Evercore ISI 3rd Annual HealthCONx conference taking place December 1-3, 2020. The company's CEO, Taylor Schreiber, and VP of Finance, Andrew Neill, will participate in a fireside chat on December 2 at 1:00 p.m. EST. The event can be accessed via a live webcast, with a replay available for 90 days post-event. Shattuck's lead programs include SL-172154 and SL-279252, both undergoing Phase 1 trials for cancer treatment.
Details
News Market Reaction – STTK
The recorded move for STTK in the trading session of this news was -2.68%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
AUSTIN, TX and DURHAM, NC, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in the Evercore ISI 3rd Annual HealthCONx conference being held December 1-3, 2020.
Conference Presentation Details
Conference: Evercore ISI 3rd Annual HealthCONx
Format: Fireside chat with Umer Raffat
Presenters: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer and Andrew Neill, Shattuck’s Vice President of Finance and Corporate Strategy
Date: December 2, 2020
Time: 1:00 p.m. EST
Webcast Link: Available Here
The live webcast of the fireside chat will be available on the Events & Presentations section of the Company’s website. A replay of the webcast will be archived for up to 90 days following the presentation dates.
About Shattuck Labs, Inc.
Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.
Investor Contact:
Conor Richardson
Director of Finance
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
Media Contact:
Stephanie Ascher
Managing Director
Stern Investor Relations, Inc.
Stephanie.ascher@sternir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.